TCM
SPRY icon

Tyro Capital Management’s ARS Pharmaceuticals SPRY Stock Holding History

Tyro Capital Management’s Portfolio SPRY Stock Details SPRY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$35.7M Buy
4,459,337
+1,490,738
+50% +$12.8M 8.01% 5
2026
Q1 		$23.8M Buy
2,968,599
+973,747
+49% +$9.33M 2.59% 9
2025
Q4 		$23.2M Buy
+1,994,852
New +$19.4M 4.3% 8

Other funds holding SPRY

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Tyro Capital Management's SPRY Position: Q2 2026 in Review

Tyro Capital Management increased its ARS Pharmaceuticals (SPRY) stake by 50% in Q2 2026, buying an estimated $12.8M and bringing the position to 4,459,337 shares worth $35.7M. The position accounts for 8.01% of the portfolio, ranked #5.

Tyro Capital Management first reported a position in SPRY in Q4 2025 and has held it in 3 quarters since. 209 funds tracked by Wall St. Rank hold SPRY as of Q2 2026.

  • Tyro Capital Management held 4,459,337 shares of ARS Pharmaceuticals worth $35.7M as of Q2 2026.
  • Tyro Capital Management bought 1,490,738 ARS Pharmaceuticals shares in Q2 2026, an estimated $12.8M.
  • ARS Pharmaceuticals made up 8.01% of Tyro Capital Management's portfolio in Q2 2026, its #5 holding.
  • Tyro Capital Management first reported a position in ARS Pharmaceuticals in Q4 2025 and has held it in 3 quarters since.
  • 209 funds tracked by Wall St. Rank held ARS Pharmaceuticals as of Q2 2026.

Based on Tyro Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.